By Inteledoc Expert Team | 10 min read | Medically reviewed by Dr. Nitin Jain, MBBS, MD EDIC — Inteledoc Medical Advisory Team
It is the first question anyone asks when they hear about semaglutide — and it deserves a direct, honest answer. How much weight can you actually lose? The clinical trial numbers are impressive. The real-world results in a properly supervised programme are genuinely transformative for many patients. But the honest answer is more nuanced than a single figure — because how much weight you lose on semaglutide depends on factors that are specific to your biology, your programme quality, and your starting point. This blog gives you the complete, evidence-based picture.
What the Clinical Trials Actually Show
The most reliable data on semaglutide weight loss comes from the STEP trial programme — six large randomised controlled trials involving thousands of patients across multiple countries. These were not small studies or short-term experiments. They represent the most rigorous investigation of any weight loss medicine in history.
📊 SEMAGLUTIDE WEIGHT LOSS — CLINICAL TRIAL RESULTS
STEP 1 (68 weeks)
Adults with obesity (no diabetes). Average weight loss: 14.9% of body weight. 86.4% of participants lost at least 5% of body weight. 69.1% lost at least 10%. 50.5% lost at least 15%.
STEP 2 (68 weeks)
Adults with obesity and type 2 diabetes. Average weight loss: 9.6% of body weight. Diabetes impairs GLP-1 response — results lower but still clinically significant.
STEP 5 (104 weeks)
Two-year extension study. Average weight loss: 15.2% of body weight — results maintained and slightly improved beyond 68 weeks with continued supervised treatment.
Best responders
Approximately 1 in 3 patients in STEP 1 lost 20% or more of body weight — results approaching bariatric surgery outcomes without surgery.
These results were achieved in properly supervised clinical programmes — with regular medical monitoring, structured dietary guidance, and integrated lifestyle support. They represent what semaglutide produces when the full clinical framework is in place.
✗ EVERYONE LOSES THE SAME AMOUNT OF WEIGHT ON SEMAGLUTIDE
Semaglutide produces a range of responses. Some patients lose 8–10% of body weight; others lose 20% or more from the same medicine and dose. The difference is not random — it is determined by biology, programme quality, and adherence. Understanding what drives your individual response is what personalised clinical assessment is for.
What Your Weight Loss on Semaglutide Will Actually Depend On
1. Your Degree of Insulin Resistance
Insulin resistance is the single most important biological variable affecting semaglutide results. Patients with significant insulin resistance — extremely common in urban Indian adults, often undiagnosed — have a body that is biologically locked in fat-storage mode. Semaglutide addresses this directly through GLP-1 receptor activation, but patients with very severe insulin resistance may need additional clinical intervention (higher doses, or switching to tirzepatide’sdual GIP/GLP-1 mechanism) to achieve maximum results.
2. Whether You Have Type 2 Diabetes
STEP 2 showed average weight loss of 9.6% in patients with type 2 diabetes — compared to 14.9% in non-diabetic patients on the same medicine. This is not because semaglutide is less effective in diabetes, but because diabetes involves significant insulin secretory impairment that limits the medicine’s full metabolic effect. Patients with diabetes can still achieve clinically meaningful weight loss — but setting realistic expectations matters.
3. The Quality of the Programme Around the Medicine
This is the factor most people underestimate. The STEP trials were not just semaglutide vs placebo — they included structured dietary counselling, regular monitoring, and lifestyle support alongside the medicine. Semaglutide taken without these elements consistently produces lower results than the trial numbers suggest. A patient on a complete supervised programme with protein targets, resistance training, and regular doctor check-ins will lose significantly more than the same patient taking semaglutide with no clinical support.
4. Protein Intake During Treatment
Semaglutide suppresses appetite significantly. Without a specific protein target, patients eat less of everything — including the protein needed to preserve muscle mass. Inadequate protein during semaglutide treatment means weight loss includes significant muscle loss alongside fat. Losing muscle reduces metabolic rate — making future weight management harder and reducing the quality of the weight lost. Inteledoc’s programmes establish protein targets (1.2–1.6g per kg body weight daily) from day one specifically to prevent this.
5. Resistance Training Integration
Patients who add regular resistance training to their semaglutide programme consistently show better body composition outcomes than those who do not — losing a higher proportion of fat relative to muscle. This is not an optional fitness add-on. It is a clinical component of an effective semaglutide weight loss programme.
6. Duration of Treatment
STEP 5 showed that weight loss continues — or is maintained — beyond 68 weeks with ongoing supervised treatment. Patients who stop at 16 weeks have not yet achieved the full potential of the medicine. A minimum 12-month active programme is what Inteledoc recommends for most patients before transitioning to a maintenance phase.
What Your Weight Loss on Semaglutide Will Actually Depend On
👤 REALISTIC WEIGHT LOSS PROJECTIONS ON A SUPERVISED SEMAGLUTIDE PROGRAMME
90 kg
Starting weight. At 14.9% average loss: ~13.4 kg over 12–18 months. At 20% (strong responder): ~18 kg.
80 kg
Starting weight. At 14.9% average loss: ~11.9 kg over 12–18 months. At 20%: ~16 kg.
100 kg
Starting weight. At 14.9% average loss: ~14.9 kg over 12–18 months. At 20%: ~20 kg.
With diabetes
Starting weight 90 kg. At 9.6% (STEP 2 average): ~8.6 kg over 12–18 months. Still clinically significant — and blood sugar improvements are substantial.
These are projections based on clinical trial averages. Your individual result will depend on the biological factors above — which is why a metabolic assessment before starting is the only reliable basis for a personalised projection.
How Semaglutide Results Compare to Everything Else
For context, clinical trials of dietary interventions alone typically produce 3–5% weight loss at 12 months, with most of it regained within two years. Commercial diet programmes produce 5–8% in the best-performing trials. Orlistat (the old prescription weight loss medicine) produces approximately 3% additional loss above placebo. Semaglutide’s 14.9% average — sustained at two years — represents a categorically different clinical result. The only intervention that consistently exceeds it is bariatric surgery, which produces 20–35% but with surgical risks, recovery time, and permanent anatomical changes that many patients appropriately want to avoid.
✓ HOW MUCH WEIGHT COULD YOU SPECIFICALLY LOSE?
The only honest answer requires knowing your biology. Inteledoc's initial metabolic assessment — thyroid function, insulin resistance, hormonal profile, nutritional status — gives your doctor the data needed to make a personalised weight loss projection specific to you. Not a trial here. average. A clinical estimate based on your actual metabolic situation Book your Assessment here.
How Semaglutide Results Compare to Everything Else
The STEP 4 trial specifically investigated what happens when semaglutide is stopped. Patients who discontinued after 20 weeks regained approximately two-thirds of their weight loss within one year. This is not a failure of the medicine — it is a predictable biological response. The hormonal defences that semaglutide was managing (elevated ghrelin, reduced leptin) reassert when the medicine stops.
Two things determine how much weight stays off after stopping: how successfully lasting dietary and lifestyle habits were built during the treatment period, and whether a structured maintenance plan is in place. Inteledoc builds both into every semaglutide programme from the very first consultation — not as an afterthought when treatment ends, but as a core component of the plan from day one.
💊 INTELEDOC PROGRAMME PLANS
3 Months Plan
GLP-1 Plan
₹4,500
Metabolic Plus
₹9,000
6 Months Plan
GLP-1 Plan
₹7,500
Metabolic Plus
₹15,000
12 Months Plan
GLP-1 Plan
₹12,000
Metabolic Plus
₹24,000
Frequently Asked Questions
The first month (0.25mg starting dose) is an adaptation phase — the goal is safe adjustment, not rapid loss. Most patients lose 0.5–1.5 kg in the first month. The rate accelerates significantly from months 2–3 as the dose increases and the appetite-reducing effect strengthens.
Individual response varies significantly based on insulin resistance level, existing health conditions (particularly diabetes), diet quality, protein intake, exercise habits, and programme quality. Both responses are real — they reflect different biology, not different effort.
Higher doses produce greater appetite suppression for most patients — which generally corresponds to greater weight loss. But the relationship is not linear, and not everyone benefits from the highest dose. Your Inteledoc doctor titrates your dose based on your individual response and tolerability.
Yes — very significantly. A 15% reduction in body weight produces measurable improvements in blood sugar, blood pressure, cardiovascular risk, liver fat, joint load, sleep apnoea severity, andhormonal balance. It is the weight loss threshold at which many of obesity’s complications begin to reverse substantially.
Aggressive fasting during semaglutide treatment is not recommended. Very low caloric intake during GLP-1 treatment significantly increases muscle loss, impairs nutritional adequacy, and can trigger the metabolic adaptation (reduced metabolic rate) that makes sustained weight loss harder. Inteledoc’s approach uses a moderate, sustainable deficit — not extreme restriction.
Yes — GLP-1 medicines produce proportionally greater reductions in visceral (abdominal) fat than in subcutaneous fat elsewhere on the body. This is clinically significant because visceral fat is the metabolically most dangerous type, producing inflammatory signals that drive insulin resistance, cardiovascular risk, and metabolic dysfunction.
Without adequate protein intake and resistance training, yes — some muscle loss alongside fat loss is common. With Inteledoc’s protein targets and exercise guidance, muscle loss is minimised and body composition outcomes are significantly better.
Any weight loss that improves your metabolic health, reduces your risk of complications, and improves your quality of life is clinically meaningful — regardless of whether it matches a population average. Your Inteledoc doctor will review your response at every check-in and adjust the programme to maximise your individual result.
Yes — if a properly managed semaglutide programme at an optimised dose produces insufficient results, switching to tirzepatide’s dual GLP-1 and GIP mechanism is the logical clinical next step. Tirzepatide clinical trials show average weight loss of 20.9% — significantly greater than semaglutide.
A metabolic assessment with an Inteledoc doctor gives you a personalised projection based on your actual biology — insulin resistance, thyroid function, hormonal profile, and health history. It is the only honest basis for a specific estimate.
Find out exactly how much weight you can lose with semaglutide
Inteledoc — India's first metabolonomics-based weight loss programme. Doctorsupervised, online across India & in-person in Gurugram. Plans from ₹1,500/month.
Book a consultation